A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression (NCT07610473)
A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression
🩺 Plain-English Summary (8th-Grade Level)
In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.
Who can join: Review the eligibility criteria below.
Location: Draig Clinical Site — Phoenix, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (22 Sites)
- Draig Clinical Site — Phoenix, Arizona
- Draig Clinical Site — Little Rock, Arkansas
- Draig Clinical Site — Bellflower, California
- Draig Clinical Site — Costa Mesa, California
- Draig Clinical Site — Lafayette, California
- Draig Clinical Site — Hialeah, Florida
- Draig Clinical Site — Orlando, Florida
- Draig Clinical Site — Orlando, Florida
- Draig Clinical Site — Tampa, Florida
- Draig Clinical Site — Tampa, Florida
- Draig Clinical Site — Decatur, Georgia
- Draig Clinical Site — Chicago, Illinois
- Draig Clinical Site — Skokie, Illinois
- Draig Clinical Site — Boston, Massachusetts
- Draig Clinical Site — New York, New York
- Draig Clinical Site — New York, New York
- Draig Clinical Site — Columbus, Ohio
- Draig Clinical Site — Allentown, Pennsylvania
- Draig Clinical Site — Media, Pennsylvania
- Draig Clinical Site — DeSoto, Texas
- Draig Clinical Site — Fort Worth, Texas
- Draig Clinical Site — Bellevue, Washington
📞 Contact the Study Coordinator
Phone: +44(0)2920028450
Email: info@draigtherapeutics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Major Depressive Disorder (MDD)
- Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression — Arlington, Texas
- Neuroimaging Markers of Midlife Depression and Cognitive Behavioural Therapy (CBT) — Toronto, Ontario
- Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts — New York, New York
- Ketogenic Diet and Neuromodulation in Treatment Resistant Depression — Toronto, Ontario
- REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness — Greenwich, Connecticut
- Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder — Toronto, Ontario
Explore by condition: All Major Depressive Disorder (MDD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.